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Purpose: XY individuals with disorders/differences of sex devel-
opment (DSD) are characterized by reduced androgenization
caused, in some children, by gonadal dysgenesis or testis regression
during fetal development. The genetic etiology for most patients
with 46,XY gonadal dysgenesis and for all patients with testicular
regression syndrome (TRS) is unknown.
Methods: We performed exome and/or Sanger sequencing in 145
individuals with 46,XY DSD of unknown etiology including
gonadal dysgenesis and TRS.
Results: Thirteen children carried heterozygous missense
pathogenic variants involving the RNA helicase DHX37, which
is essential for ribosome biogenesis. Enrichment of rare/novel
DHX37 missense variants in 46,XY DSD is highly significant
compared with controls (P value= 5.8 × 10−10). Five variants
are de novo (P value= 1.5 × 10−5). Twelve variants are clustered
in two highly conserved functional domains and were
specifically associated with gonadal dysgenesis and TRS.
Consistent with a role in early testis development, DHX37 is
expressed specifically in somatic cells of the developing human
and mouse testis.
Conclusion: DHX37 pathogenic variants are a new cause of an
autosomal dominant form of 46,XY DSD, including gonadal
dysgenesis and TRS, showing that these conditions are part of a
clinical spectrum. This raises the possibility that some forms of
DSD may be a ribosomopathy.
Genetics in Medicine (2019) https://doi.org/10.1038/s41436-019-
0606-y
Keywords: disorders of sex development (DSD); testicular
regression syndrome; DHX37; RNA helicase; ribosomopathy
INTRODUCTION
Disorders/differences of sex development (DSD) are defined as
congenital conditions with discordant development of chro-
mosomal and gonadal/anatomical sex and cover a wide range
of phenotypes that involve the endocrine and reproductive
systems.1 A subgroup of DSD consists of individuals with
anomalies of testicular formation or the maintenance of
testicular tissue during early embryonic development. The
former comprises 46,XY complete or partial gonadal dysgen-
esis (MIM 400044). The complete form is characterized by
female external genitalia, well-developed Müllerian structures,
and gonads of fibrous ovarian-like stroma with no evidence of
testicular differentiation.2 46,XY partial gonadal dysgenesis is
characterized by partially developed internal ducts usually
consisting of a mixture of Wolffian (epididymis, vas deferens,
and seminal vesicle) and Müllerian ducts (fallopian tube,
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uterus, and upper third of the vagina) with varying degrees of
virilization of the external genitalia depending on the amount
of testicular tissue present.2
46,XY testicular regression syndrome (TRS) is defined by a
46,XY chromosome complement, ambiguous or atypical
genitalia, anomalies of sexual duct formation, and absence of
gonadal tissue on one or both sides (MIM 273250).3–5 Some
boys with TRS are born with normal external genitalia but
present with cryptorchidism and may even have one or both
palpable testes that subsequently involute. Children with TRS
are considered to have variable degrees of testicular determi-
nation with the loss of gonad tissue early in gestation before
testis formation is complete. The exact prevalence of TRS is
unknown, but has been estimated to affect approximately
1:2000 boys.6 Anorchia is defined by the complete absence of
testicular tissue in a 46,XY phenotypic male. However, since
male-typical differentiation of the genital tract and the
development of the external genitalia are dependent on
the production of anti-Müllerian hormone (AMH) and
androgens, the testis must have been present at least up to
the 16th week of gestation in these individuals.7 In some
circumstances anorchia may occur secondary to a vascular
event or testicular torsion.8 Bilateral congenital anorchia has a
prevalence of approximately 1:20,000 males and unilateral
congenital anorchia a prevalence of 1:6500 males.9
Determining the genetic etiology of 46,XY gonadal dysgen-
esis and 46,XY TRS has been challenging. No gene pathogenic
variants have been reported in association with the latter and
in the former pathogenic variants in SRY (MIM 480000),
NR5A1 (encoding steroidogenic factor-1, SF-1; [MIM
184757]), andMAP3K1 (MIM 600982) are the most prevalent
causes, but together explain less than 40% of all 46,XY
gonadal dysgenesis.10 Pathogenic variants in other genes
including SOX9 (MIM 608160), SOX8 (MIM 605923), GATA4
(MIM 600576), DMRT1 (MIM 602424), FOG2 (MIM
603693), WT1 (MIM 607102), DHH (MIM 605423), CBX2
(MIM 602770), ATRX (MIM 300032), FGF9 (MIM 600921),
and ZNRF3 (MIM 612062) are reported in rare individuals as
a cause of both syndromic and nonsyndromic forms of 46,XY
gonadal dysgenesis as well as some 46,XY boys with severe
penoscrotal hypospadias.10–12 The families of some patients
with TRS raised as male also include other children with
complete or partial 46,XY gonadal dysgenesis or agonadism
who are raised as female.4,5,13,14 Thus, both 46,XY gonadal
dysgenesis and TRS can be regarded as a continuum of
phenotypes due to errors in testis determination and
maintenance rather than clearly distinct and unrelated
categories of atypical testicular formation.14 Though TRS is
part of the clinical spectrum of 46,XY gonadal dysgenesis and
may share a common genetic etiology, identification of the
gene(s) involved has proven elusive.
Here, using exome and Sanger sequencing approaches for
145 individuals with 46,XY DSD of unknown etiology, we
identified recurrent pathogenic variants in the DEAH-box
RNA helicase DHX37 specifically in association with 46,XY
gonadal dysgenesis and 46,XY TRS.
MATERIALS AND METHODS
Patient and control samples
We studied 145 cases with 46,XY DSD of unknown etiology.
They were defined as 46,XY gonadal dysgenesis (n= 81), 46,
XY TRS (n= 16), 46,XY boys with severe penoscrotal
hypospadias (n= 33), and 46,XY anorchia (n= 15). All
patients were screened for pathogenic variants in genes
known to cause DSD either by analysis of exome data sets or
by direct Sanger sequencing of candidate genes. All patients
with 46,XY DSD met the revised criteria of the Pediatric
Endocrine Society (LWPES)/European Society for Paediatric
Endocrinology (ESPE). This study was approved by the local
French ethical committee (2014/18NICB—registration num-
ber IRB00003835) and consent to genetic testing was obtained
from adult probands or from the parents when the patient
was under 18 years. Patient ancestry was determined by self
reporting, based on responses to a personal questionnaire,
which asked questions pertaining to the birthplace, languages,
and self-reported ethnicity of the participants, their parents,
and grandparents. Genes known to be involved in 46,XY DSD
were screened for pathogenic variants in the XY DSD cohort
and high-resolution array comparative genomic hybridization
(aCGH) was performed on all cases and indicated normal
ploidy in all cases.
Exome sequencing
One hundred patients presenting with 46,XY DSD were
sequenced using the exome approach as described else-
where.11 Exon enrichment was performed with Agilent
SureSelect Human All Exon V4. Paired-end sequencing was
performed on the Illumina HiSeq2000 platform with TruSeq
v3 chemistry. Read files (fastq) were generated from the
sequencing platform via the manufacturer’s proprietary
software. Reads were mapped with the Burrows–Wheeler
Aligner, and local realignment of the mapped reads around
potential insertion/deletion (indel) sites was carried out with
GATK version 1.6. Duplicate reads were marked with Picard
version 1.62 (http://broadinstitute.github.io/picard/). Addi-
tional BAM file manipulations were performed with SAM-
tools (0.1.18). Single-nucleotide polymorphism (SNP) and
indel variants were called with the Genome Analysis Toolkit
(GATK) Unified Genotyper for each sample. SNP novelty was
determined against dbSNP138. Novel variants were analyzed
by a range of web-based bioinformatics tools with the
EnsEMBL SNP Effect Predictor (http://www.ensembl.org/
homosapiens/userdata/uploadvariations). All variants were
screened manually against the Human Gene Mutation
Database Professional Biobase (http://www.biobase-
international.com/product/hgmd/). In silico analysis was
performed to determine the potential pathogenicity of the
variants. Potentially pathogenic variants were verified with
classic Sanger sequencing.
Sanger sequencing of the entire coding sequence of DHX37
Sanger sequencing was performed for the DHX37 gene in 45
patients with 46,XY gonadal dysgenesis (n= 30), 3 patients
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with testicular regression syndrome, and 12 patients with
anorchia. Polymerase chain reaction (PCR) amplification
and Sanger sequencing of DHX37 was performed using
the primers listed in Table S1. The conditions for PCR were
95 °C for 5 minutes followed by 35 cycles of 95 °C for
30 seconds, 58.5 °C for 30 seconds, and 72 °C for 30 seconds.
DNA sequence analysis was performed using at least 200 ng of
purified DNA, 20 ng of primer and fluorescently labeled Taq
DyeDeoxy terminator reaction mix (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s
instructions. DNA sequence was determined using a 373A
automated DNA sequencer (Applied Biosystems).
Structural modeling
The homologous 2.6 Å crystal structure of Prp43-ADP-BeF3-
U7-RNA complex (PDB: 5LTA)15 was used as a template to
generate a homology model using SWISS-MODEL15–20
(https://swissmodel.expasy.org/). This model was chosen as
the template because it had the highest score in models
complexed with RNA and adenosine triphosphate (ATP) in
the local alignment using BLAST (https://blast.ncbi.nlm.nih.
gov/Blast.cgi) against the Protein Data Bank (PDB) data-
base.21 Specific variants were made on the generated model
using Chimera 1.1122 with the swapaa function. The single-
stranded RNA motif and ADP-BeF3 of the 5LTA model was
retained and used to view possible RNA and ATP contacts of
the DHX37 pathogenic variants.
Annotations from UniProtKB (https://www.uniprot.org/
uniprot/Q8IY37) and Pfam (http://pfam.xfam.org/protein/
Q8IY37) were used as a guide to mark the domains in the
structural model of DHX37. Some adjustments were made as
compared with UniprotKB and Pfam based on the structu-
rally defined domains of the DEAH-box family.23
Collection of human fetal gonads and human
immunohistochemistry
Human fetal gonads were isolated from material available
following elective surgical termination of pregnancy during
the first trimester at the Department of Gynecology
at Copenhagen University Hospital (Rigshospitalet) and
Hvidovre Hospital, Denmark. The regional ethics
committee approved this study (permit number H-1-2012-
007) and women gave their informed written and oral
consent. None of the terminations were for reasons of
fetal abnormality and all fetuses appeared morphologically
normal. The fetuses in this collection were between
gestational week (GW) 7 and 12, with fetal age determined
by scanning crown–rump length. Fetal testis tissue was
isolated in ice-cold phosphate buffered saline (PBS) and
immediately fixed in formalin. Immunohistochemistry was
conducted as previously described with anti-DHX37
(HPA047607, Sigma/Prestige Antibodies) diluted 1:50 and
antigen retrieval in TEG buffer (10 mM Tris, 0.5 mM EGTA,
pH 9.0).24 Immunofluorescence was conducted as previously
described,25 with anti-DHX37 (HPA047607, Sigma/Prestige
Antibodies) diluted 1:200 and anti-OCT4 (sc-5279, Santa
Cruz Biotechnology) diluted 1:100. Immunofluorescence on
the human cell lines RT4, KGN, and HEK 293 was performed
as described elsewhere10 using anti-DHX37 (HPA047607,
Sigma/Prestige Antibodies) diluted 1:200.
Expression profiling in developing mouse gonads
For quantitative reverse-transcription PCR (qRT-PCR) of
mouse tissue, messenger RNA (mRNA) was extracted from
subdissected gonads of 6 XX and 6 XY 11.5 dpc mouse
embryos using the RNeasy Plus Micro Kit (Qiagen). Each
sample was then mixed with FastSYBR green master mix
(Applied Biosystems) and either Dhx37 or Hrpt1 primers,
plated in duplicate, and run on a 7500 Fast Real-Time PCR
System (Applied Biosystems). Whole-mount in situ hybridi-
zation of 11.5 dpc wild-type (WT) XY gonads has been
previously described.26 Immunofluorescence staining with
anti-DHX37 (HPA047607, Sigma/Prestige Antibodies), anti-
OCT4 (SC-5279, Santa Cruz Biotechnology), and DAPI
(Vectashield with DAPI, Vector Laboratories) was performed
on transverse sections of 11.5 dpc XY gonads. Sections were
imaged at 20× using an LSM 700 Inverted Confocal
Microscope (Zeiss).
Site-directed mutagenesis
DHX37 expression vectors containing the all six missense
pathogenic variants were generated by site-directed mutagen-
esis (QuikChange, Stratagene) with the use of WT DHX37
complementary DNA (cDNA) in both pAC-GFP and
pCMV6-Myc expression vectors as templates. The entire
coding sequence of all mutant plasmids was confirmed by
direct sequencing prior to functional studies. The pcDNA-
SOX9-Flag vector was a gift from Francis Poulat (Institut de
Génétique Moléculaire de Montpellier, France).
Single-cell array analysis of Nr5A1+, XY somatic cells of the
developing murine gonad
We analyzed public single-cell RNA-seq (scRNA-seq) data from
Nr5A1+ cells of the developing XY murine gonad as described
elsewhere.27 The data correspond to expression of transcript
with fkpm >1 at single-cell level in the developing male murine
gonad at specific time points in embryonic development (E10.5,
E11.5, E12,5, E13.5, and E16.5). The data were compiled into a
spreadsheet that was used to generate a box and whisker
plot using BioVinci data visualization package. The
summary statistics used to create the box and whisker plot
included the median of the data, the lower and upper quartiles
(25% and 75%), and the minimum and maximum values array
analysis.
Cellular localization
Cellular localization of both WT-DHX37 and DHX37 mutant
proteins were assayed by transfecting the different plasmids
into HEK 293-T cells with the use of FuGENE HD (E231A,
Promega) in chamber slides (C7182, 8 wells, Nunc) as
described elsewhere10 using green fluorescent protein (GFP)
signal from the DHX37-GFP WT and mutants, as well as
MCELREAVEY et al ARTICLE
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antifibrillarin antibody (ab4566, Abcam) diluted 1:200.
Images were obtained with a Leica Microsystems DMI4000B
microscope at 100× magnification.
RESULTS
Genetic analysis of 46,XY DSD reveals DHX37 pathogenic
variants
A genetic screen of 145 46,XY individuals with DSD of
unexplained etiology identified 13 individuals who har-
bored recurrent and de novo heterozygous missense
pathogenic variants involving six different amino acids in
the putative RNA helicase DHX37. Pathogenic variants
were specifically identified in children with 46,XY gonadal
dysgenesis (9/81, 11%) and 46,XY TRS (4/16, 25%) but not
in boys with either severe penoscrotal hypospadias or
anorchia (Table 1 and 2). All amino acid changes, with the
exception of the p.G1030E and p.R308Q pathogenic
variants, are absent from public databases. The p.G1030E
substitution is a very rare variant with a minor allelic
frequency (MAF) of 4.9 × 10−5 in individuals of European
ancestry (ExAC database http://exac.broadinstitute.org/),
whereas the p.R308Q is absent from the ExAC
database but is reported in one individual by genomic
sequencing in the gnomAD database (http://gnomad.
broadinstitute.org/). Combining both data sets indicates
that this pathogenic variant has a MAF of 6.7 × 10−6. Five
of six pathogenic variants analyzed were absent from either
parent and are therefore de novo. One pathogenic variant,
p.T304M was maternally inherited and the mode of
inheritance in the remaining seven children is unknown
because DNA from the parents was not available for study.
The presenting phenotypes of children carrying pathogenic
DHX37 pathogenic variants exist on a spectrum ranging
from phenotypic females to males with bilateral or
unilateral cryptorchidism (Table 1). However, of note the
majority of pathogenic variants were associated with the
presence of Wolffian and absence of Müllerian structures
suggesting residual Sertoli and Leydig cell function during
early testis formation (Fig. 1). No gonadal tissue was
present following examination for four of the children. In
all 13 children there was no evidence of any other somatic
anomalies. All pathogenic variants were confirmed by
Sanger sequencing.
DHX37 is one the most highly conserved genes in the
human genome and is intolerant to loss-of-function and
missense variants in the general population.28 Fisher’s exact
test (two-tailed) on the frequency of loss-of-function and
missense variants observed in our 46,XY DSD cohort,
compared with rare (MAF < 0.01%) missense variants in the
DHX37 gene from 32,500 control individuals of matched-
ancestry (ExAC database), shows a highly significant enrich-
ment of rare missense variant in the DHX37 gene in the overall
DSD cohort (P value= 5.8 × 10−10). The association with the
subgroups of 46,XY gonadal dysgenesis and 46,XY TRS is even
more striking (P value= 6 × 10−12). If we consider the five de
novo missense pathogenic variants in DHX37 and compare
this with the frequency of de novo missense DHX37 variants in
2278 control individuals (denovo-db.gs.washington.edu), the
DSD cohort is highly enriched for de novo variants (P value=
1.5 × 10−5). This may indeed be an underestimation because
the inheritance of the DHX37 pathogenic variant was
unknown in 7/13 children. Furthermore, in the family of
patient 5, the pathogenic variant was both de novo and absent
from the unaffected 46,XY brother.
Interestingly, with one exception, all pathogenic variants are
clustered within the functional RecA1 and RecA2 domains of
the protein and involve amino acid residues that are highly
conserved through to yeast (Fig. 2a and Supplemental Fig. 1).
Consistent with this finding, all amino acid changes are
considered to be highly damaging by multiple predictive
software programs. Eleven of the 13 children have pathogenic
variants specifically in four amino acid residues. Five children
were mutated for the R308 residue and two children each for
the T304, R334, and R674 residues respectively. None of the
13 children carrying pathogenic variantss in DHX37 carried
pathogenic variants in other genes known to cause 46,XY
DSD.
In silico conservation and modeling of DHX37 amino acid
substitutions
RNA helicases are characterized by a highly conserved core
domain of two tandem RecA-like domains (RecA1: ATP-
binding DEAH-box helicase, RecA2: C-terminal helicase),
which are connected by a flexible linker (Fig. 2a).29,30 Within
these domains are 11 sequence motifs conserved throughout
to yeast, which are involved in RNA substrate interaction,
nucleoside triphosphate (NTP) binding and hydrolysis, and
the coordination of unwinding activity. Four of the patho-
genic variants fall within the motifs Ia, Va, and VI, which
have been implicated in RNA binding, coordination of ATP
binding and unwinding, and ATP binding and hydrolysis
respectively (Fig. 2b). To predict the molecular consequences
of the pathogenic variants we generated homology models of
DHX37 using a crystal structure of the DEAH-box helicase
Prp43 (PDB ID:5LTA) in an active state complexed with
single-stranded U7-RNA and a nonhydrolyzable ATP analog
(ATP-BeF3).
15
The pathogenic variants p.R308Q, p.R334L are located at
the DNA/RNA contact interface and provide an electro-
static environment to accommodate nucleic acids (Fig. 2a,
c). These two arginines (R308 and R334) are highly
conserved within the DEAH-box family and their counter-
parts in Prp43 interact with the RNA backbone.15 The
recurrent p.R308Q pathogenic variant found within the
conserved sugar-phosphate binding site, Ia, removes a
positive charge and likely weakens this interaction.31 The
p.R334L substitutions a hydrophobic leucine at conserved
positions otherwise occupied by charged or polar amino
acids with predicted detrimental effects on DNA/RNA-
binding. The variants p.S626L and p.R674Q map to
sequence motif Va or VI, respectively, which are both
involved in ATP binding, hydrolysis, and cross-talk with
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the unwinding machinery (Fig. 2d). Serine 626 interacts
with water and magnesium in the active site and arginine
674 forms electrostatic interactions with the γ-phosphate
of ATP. The residue p.T304 of motif Ia is not directly
involved in RNA binding but mediates intramolecular
packing, which would be affected by the bulkier methio-
nine side-chain introduced in the p.T304M pathogenic
variant (Fig. 2e). Further evidence in favor of causality of
these pathogenic variants is indicated by the analysis of
seven missense variants reported in the gnomAD/ExAC
databases that are present in low frequencies in the general
population and may not be pathogenic (Table S2). These
are located in the RecA1 and RecA2 domains. In silico
modeling of all seven low frequency non-pathogenic variants
indicated that in contrast to the pathogenic variants, they are
predicted not to have either major structural or functional
consequences (Supplemental data and Fig S2).
Expression analysis of DHX37 in early gonad development
and functional studies
Consistent with a role in testis determination and early testis
development, DHX37 is expressed exclusively in somatic cell
lineages of the mouse and human gonad during testis
determination and development (Fig. 3). The highest
concentration of the protein is at the nuclear membrane,
although protein is also observed in the cytoplasm and in the
nucleolus of some cells (Fig. 3). Analysis of protein expression
in different tissues from adults reveals that DHX37 is
highly localized at the nuclear membrane in multiple
human and mouse cell lines (https://www.proteinatlas.org/
ENSG00000150990-DHX37/cell). Although expression was
not observed in germ cells in fetal gonads, in adult human
Table 2 Summary of the frequency of DHX37 pathogenic
variants found in association with each 46,XY DSD subtype
Phenotype DHX37 Amino
acid change
Frequency
46,XY Gonadal dysgenesis
(n= 81)
p.T304M (2), p.R308Q
(4), p.R334L, R674Q (2)
9/
81 (11%)
46,XY Testicular regression
syndrome (n= 16)
p.R308Q, p.R334W,
p.S626L, p.G1030E
4/
16 (25%)
46,XY DSD (boy with
penoscrotal hypospadias)
(n= 33)
- 0
46,XY Anorchia (n= 15) - 0
DSD disorders/differences of sex development.
0.5 mm
a b
c d e f
100 µm
100 µm 250 µm 250 µm 50 µm
Fig. 1 Histologic analysis of gonad samples from three affected children. (a) Right gonad of patient 12 with no evidence of testicular tissue and, at
higher magnification in (b) epididymal-like structure. (c) Left “streak” gonad of homogeneous fibrous-like stromal tissue from the same child. (d–e)
Histology from patient 10. No gonadal tissue was observed, however remnants of the ductus deferens were present on the sample from the right side (d,
black arrows) and epididymal-like tissue was observed on the left side (e). (f) Epipidymal-like structures from patient 6. Size bars are indicated for each panel.
Staining was performed with hematoxylin–eosin–saffron.
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testes the protein is mainly localized in spermatogonia
(Fig. S3; https://www.proteinatlas.org/ENSG00000150990-
DHX37/tissue/testis#img). Single-cell expression analysis of
Nr5a1+ somatic cells of the developing XY mouse gonad also
indicates that Dhx37 is coexpressed with the sex-determining
gene Sox9 in a proportion of cells (Fig. S4). When transfected
into HEK 293 cells, the wild-type DHX37 protein and all six
mutant proteins showed localization to the nucleolus
(Fig. S5).
DISCUSSION
We provide compelling genetic evidence that specific variants
in the DEAH-box protein DHX37, which encodes a putative
RNA helicase, are a frequent cause of nonsyndromic 46,XY
gonadal dysgenesis as well as TRS. The frequency of
pathogenic variants associated with gonadal dysgenesis of
11% is similar to that described previously for each of the
genes SRY, NR5A1, and MAP3K1.10 Where tested, all
pathogenic variants are de novo with one exception, which
was inherited from the phenotypically normal mother. This
suggests that the penetrance of the variants is high and that
the phenotype is sex-limited.
In contrast to the range of phenotypes associated with
variants in other testis-determining genes, pathogenic variants
involving DHX37 are associated with TRS but not anorchia.
Children with TRS and with either female or ambiguous
external genitalia are considered to have had a normal testis
determination but have then lost testicular tissue at a critical
period during the first 16 weeks of gestation. The genital
phenotype may range predominantly from male to female,
including marked sex ambiguity depending on the duration of
normal testicular function prior to the loss of testicular tissue.
Previously, a child with a pathogenic variant in the testis-
determining factor NR5A1 (p.V355M) was reported, who
presented with bilateral anorchia and reduced penile length;
however, his dizygotic twin brother was also heterozygous for
the change yet had normal development, suggesting that other
genetic factors may be involved.32 Here, we found that 25% of
children with clinically well-defined TRS carried pathogenic
variants in the DHX37 gene. These data indicate that DHX37
has critical roles not only in early human testis determination
but also in the maintenance of testicular tissue during an early
phase of testis development. They also establish that 46,XY
gonadal dysgenesis and TRS can be part of the same clinical
spectrum with the same underlying genetic etiology.
The external genitalia of children carrying DHX37 patho-
genic variants ranged from completely female to male with
bilateral cryptorchidism. Four of the 13 children had virilized
HA2 OB
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Fig. 2 In silico modeling of DHX37 RecA1 and RecA2 pathogenic variants. (a) Functional domains of a homology model of DHX37 protein with U7-
RNA (dark blue) and a nonhydrolyzable adenosine triphosphate (ATP) analog (ADP-BeF3, spheres). Domains are color-coded and labeled, conserved motifs
are specified in circles, and the five disease-associated variants are indicated. The protein has four functional domains: two RecA-like domains, which are the
helicase domains (RecA1: ATP-binding DEAH-box helicase, yellow, RecA2: C-terminal helicase, green); helicase associated 2 domain (HA2, red); and
oligonucleotide/oligosaccharide-binding like domain (OB, pink). (b) Schematic diagram of the RecA-like domains in DEAH-box RNA helicases. Colors
represent main helicase functions. Alignment of human (top) and Saccharomyces cerevisiae (bottom) showing the positions of recurrent variants causing 46,
XY disorders/differences of sex development (DSD) with the consensus sequence shown in the middle. (c) Zoomed-in view of residue 308 and 334 with
single-stranded RNA. (d) Residues 626 and 674 are shown to interact with the ATP analog. (e) Residue 304 is highlighted to be buried with a pocket within
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external genitalia and were raised as male suggesting that
functional Leydig cells were present during fetal development.
There is no evidence for a genotype/phenotype correlation.
For example, five children carried the recurrent p.R308Q
pathogenic variant with a phenotype that varied from female
with primary amenorrhea to male with micropenis and
bilateral cryptorchidism.
The yeast ortholog of DHX37, Dhr1, is required for
ribosome biogenesis.33–35 Dhr1 is a essential component of
the small subunit (SSU) processome, where its activity drives
the transition of the SSU processome to pre-40S maturation
pathway.35 Recently, the human DHX37 protein was also
shown to be required for maturation of the small ribosomal
subunit in the nucleolus of human HeLa cells by interacting
with similar protein partners and small nucleolar RNAs
suggesting that this function is conserved in eukaryotes.36
Two homozygous variants in DHX37 have been suggested
to cause severe microcephaly, intellectual disability, and
cortical atrophy in two unrelated individuals.37 However,
both variants (p.R487H and p.N419K) are not located within
known conserved and functional domains of RecA1 and
RecA2. Although there was no statistical evidence in favor of
pathogenicity, these pathogenic variants may have resulted in
a severe congenital phenotype due to their homozygosity,
location within the protein, and/or they may represent
hypermorphic or neomorphic pathogenic variants. Further
genetic investigations of this syndromic form of congenital
microcephaly are required.
Disorders associated with ribosome biogenesis, the riboso-
mopathies, are an emerging and poorly understood branch of
medicine.38,39 Indeed, three human ribosomopathies are
caused by pathogenic variants in other components of the
SSU processome: UTP4 (MIM 607456) pathogenic variants
and North American Indian childhood cirrhosis (NAIC; MIM
604901); UTP14 (MIM 300508) with infertility, ovarian
cancer, and scleroderma; and EMG1 (MIM 611531) with
Bowen–Conradi syndrome (MIM 211180).38,39 The mechan-
ism(s) of how a pathogenic variant in a widely expressed
protein involved in a basic cellular function can generate a
highly specific human phenotype are unknown. However, a
zebrafish Dhx37 missense mutant has been reported in
association with anomalies in the production of glycine
receptor mRNAs, leading to an impact on neuron glycinergic
synaptic transmission and altered behavior.40 This suggests
that DHX37 may be involved in precursor mRNA (pre-
mRNA) splicing with substrate specificity for certain
transcripts at least in some cell lineages. These data raise
the intriguing possibility that some forms of 46,XY DSD,
2
a d
b c
0
XX
XY 21ts
XX
XY
XY 19ts
sex
XY
D
H
X3
7
D
H
X3
7
Dhx37
D
hx
37
Dhx37 relative expression to Hrpt1 Human fetal testis (GW 10)
R
el
at
ive
 e
xp
re
ss
io
n
1
D
H
X3
7/
O
CT
4/
DA
PI
D
H
X3
7/
O
CT
4
D
H
X3
7/
O
CT
4/
DA
PI
Fig. 3 Expression of DHX37 in mouse and human developing testis. (a–c) Expression in embryonic mouse gonads at sex-determining stage of 11.5
dpc (17–21 tail somites [ts]). (a) Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis of Dhx37 in wild-type (WT) mouse gonads
reveals no significant difference in expression between XX and XY (p= 0.056, Student’s t test). Expression is relative to Hrpt1; error bars represent standard
error. (b) Whole-mount in situ hybridization reveals Dhx37 expression in WT XY gonad (to the left of the dashed line). Signal appears stronger towards the
coelomic surface. (c) Immunofluorescence of transverse sections of WT XY gonad (left of the dashed line) showing DHX37 (green), OCT4 (red, primordial
germ cells), and DAPI (blue). DHX37 protein is concentrated around the nuclear membrane in most cells, although this is not the case in germ cells (arrows).
Cells of the mesonephros (right of the dashed lines) are also positive for Dhx37/DHX37 (b, c). (d) DHX37 protein examined in human fetal testis. No protein
is observed in gonocytes (marked with arrows), while protein is found in Sertoli cells (marked with asterisk) and in a subpopulation of the interstitial cells.
Sample is from a gestational week (GW) 10 fetus. Counterstaining with Mayer’s hematoxylin, scale bar corresponds to 50 µm.
ARTICLE MCELREAVEY et al
8 Volume 0 | Number 0 | Month | GENETICS in MEDICINE
caused by anomalies of early testis development, are also
ribosomopathies.
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